Clinical study of new bioactive materials for adults'permanent molar pulp preservation

MENG Rong; WANG Chao; MENG Yuan; LI Hong

doi:10.15956/j.cnki.chin.j.conserv.dent.2025.09.003

Abstract：Objective To explore the clinical efficacy of new bioactive materials as a direct pulp capping agent in treating adults'reversible pulpitis.Methods A randomized controlled clinical research was done from January 2023 to September 2024 and patients with carious reversible pulpitis of permanent molars were taken as the research samples in the Department of Endodontics at our institution.The patients were randomly allocated to the TheraCal LC group(experimental group)and the iRoot BP Plus group(control group),which were treated with TheraCal LC or iRoot BP Plus respectively for direct pulp capping treatment.Review the patients at 3 months,6 months,and 12 months postoperatively,and compare the success rates of treatment,incidences of adverse reactions and intraoperative operation times between the two groups were also compared.Results 65 subjects were included in the experiment,including 34 in TheraCal LC group and 31 in iRoot BP Plus group.There was no significant difference in the success rate between the two groups at 3 months,6 months and 12 months after treatment(P>0.05);the incidence of adverse effects was not statistically different between the two groups(P>0.05);The operation time in TheraCal LC group was was less than that of the iRoot BP Plus group(P<0.05).Conclusion In the treatment of adult first permanent molars with carious pulp exposure,iRoot BP Plus and TheraCal LC have positive clinical impact,and TheraCal LC is more cost-effective and time-efficient.